drugset / Trial / NCT02057172
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus (T2DM).
Timeline
- Start
- 2014-01
- Primary completion
- 2014-10
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efpeglenatide | Peptide | 0.3 mg | Subcutaneous |
| Subject | Efpeglenatide | Peptide | 1 mg | Subcutaneous |
| Subject | Efpeglenatide | Peptide | 2 mg | Subcutaneous |
| Subject | Efpeglenatide | Peptide | 3 mg | Subcutaneous |
| Subject | Efpeglenatide | Peptide | 4 mg | Subcutaneous |
| Comparator | Liraglutide | Peptide | 1.8 mg | — |